In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

This bipartisan legislation prevents further cuts, provides a modest inflationary adjustment to help ease the cost of care, ...

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Some regulatory changes are already set to happen this year, but reduced regulation under the new administration could have a ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

At today's confirmation hearing, Democratic senators were skeptical of the HHS Secretary nominee Robert F. Kennedy Jr.'s ...